Epclusa (sofosbuvir/velpatasvir)

Many patients pay $0 through manufacturer patient assistance programs. Contact our pharmacists — we handle all the paperwork.

Epclusa is a pan-genotypic HCV treatment for adult and pediatric patients with or without cirrhosis. It combines sofosbuvir and velpatasvir in one pill taken once daily without food restrictions. Treatment duration is 12 weeks for most patients.

Epclusa achieves sustained virologic response (SVR12) — considered a functional cure — in over 95% of patients across all HCV genotypes. Our pharmacists provide complete treatment management support.

• Pan-genotypic single-tablet therapy
• 12-week treatment course
• >95% cure rate across all genotypes
• No food restrictions